Share on StockTwits

Research analysts at Jefferies Group boosted their target price on shares of Cubist Pharmaceuticals (NASDAQ:CBST) from $87.00 to $88.00 in a report released on Monday. The firm currently has a “buy” rating on the stock. Jefferies Group’s target price would indicate a potential upside of 21.82% from the stock’s previous close.

Other equities research analysts have also recently issued reports about the stock. Analysts at Gabelli initiated coverage on shares of Cubist Pharmaceuticals in a research note on Friday. They set a “buy” rating on the stock. Separately, analysts at Zacks reiterated a “neutral” rating on shares of Cubist Pharmaceuticals in a research note on Thursday. They now have a $72.00 price target on the stock. Finally, analysts at Ned Davis Research upgraded shares of Cubist Pharmaceuticals from a “sell” rating to a “neutral” rating in a research note on Monday, April 28th. Six investment analysts have rated the stock with a hold rating and ten have given a buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $75.43.

Cubist Pharmaceuticals (NASDAQ:CBST) traded down 1.61% during mid-day trading on Monday, hitting $71.08. The stock had a trading volume of 767,618 shares. Cubist Pharmaceuticals has a one year low of $48.23 and a one year high of $82.12. The stock has a 50-day moving average of $68.15 and a 200-day moving average of $70.45. The company’s market cap is $5.353 billion.

Cubist Pharmaceuticals (NASDAQ:CBST) last issued its quarterly earnings data on Tuesday, April 22nd. The company reported $0.30 earnings per share for the quarter, missing the analysts’ consensus estimate of $0.33 by $0.03. The company had revenue of $261.20 million for the quarter, compared to the consensus estimate of $285.24 million. During the same quarter last year, the company posted $0.34 earnings per share. Cubist Pharmaceuticals’s revenue was up 13.6% compared to the same quarter last year. Analysts expect that Cubist Pharmaceuticals will post $0.58 EPS for the current fiscal year.

Cubist Pharmaceuticals, Inc (NASDAQ:CBST) is a biopharmaceutical company focused on the research, development and commercialization of therapies to treat serious medical conditions in acutely ill patients who are hospitalized or are being treated in other acute care settings.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.